首页> 外文会议>World biomaterials congress >Novel in-situ setting bioglass based calcium phosphate bone cements
【24h】

Novel in-situ setting bioglass based calcium phosphate bone cements

机译:新型原位固化生物玻璃基磷酸钙骨水泥

获取原文

摘要

Background: Calcium phosphate cements (CPCs) have been widely used as an alternative to biological grafts as they present excellent biocompatibility and osteoconductive properties. Novel work has successfully introduced Bioglass (BG) into (ⅰ) hydroxyapatite, (ⅱ) octacalcium phosphate and (ⅲ) fluorohydroxyapatite cements without compromising the setting time. The aim of this study was to investigate bone formation and contact to these three novel BG/CPC cements following implantation in an ovine femoral condyle critical-sized defect. Our hypothesis was that the novel cements would augment bone formation to equal amounts when compared with a commercially available calcium phosphate cement (Hydroset™). Methods: Twenty-four 8 × 15 mm deep defects were created In the medial femoral condyles of 6 female, skeletally mature commercially cross-bred sheep. Cements investigated were BG/CPC composites, however the calcium phosphate component was composed of either (1) OCP/Brushite (OCP), (2) a fluorohydroxyapatite (FHA) or (3) hydroxyapatite (HA). Groups were compared with (4) Hydroset™, a commercially available calcium phosphate cement. Cements remained in vivo for 12 weeks (n=6). Fluorochrome markers were used to measure bone apposition rates and following retrieval, specimens were processed for undecalcified histology. A thin section was made through the centre of each defect and image analysis techniques used to quantify bone apposition rates and bone-implant contact at 12 weeks post surgery. The compressive strength (MPa) of each of the cements was tested using an indentation method (Zwick Praline 500) following retrieval. Mann Whitney U tests were used for statistical analysis where p<0.05 was considered significant. Results: Results showed that significantly increased apposition rates were measured in the Hydroset™ group (mean, 1.191 ± 0.345 μm/day-1) when compared with OCP filled (mean, 0.740 ± 0.156 μm/day-1) (p = 0.028) and FHA defects (mean, 0.839 ± 0.141 μm/day-1) (p = 0.047). No significant difference was found when Hydroset™ and HA samples were compared. Significantly increased bone turnover rates were measured adjacent to the HA cement (mean, 1.151 ± 0.274 μm/day-1) when compared with OCP samples (p - 0.028). No other significant differences were found. The greatest amount of bone-cement contact was measured in the OCP group (mean, 95.47 ± 3.22%). Lowest bone-cement contact values were measured in HA samples (mean, 93.02 ± 2.32%). Significantly less bone contact was measured in HA samples when compared with FHA samples (mean, 94.55 ± 1.77%) (p = 0.014). No other significant differences were found (Figure 1). Mechanical testing showed the compressive strength of cements in each of the groups were similar (Figure 2).. Light and backscattered scanning electron microscopy showed mature lamellar bone in contact with all cement surfaces (Figure 3). Conclusion: The incorporation of fluoride within the hydroxyapatite lattice and the formation of OCP/Brushite BG/CPCs were seen to be as bioactive as the commercially available calcium phosphate cement Hydroset™. These cements are able to be injected and their compressive strength once set, and after 12 weeks in vivo, indicates that they may be excellent bone void fillers and may have potential uses for vertebroplasty applications. Further work is needed to assess the resorbability of the cements over time.
机译:背景:磷酸钙水泥(CPC)具有出色的生物相容性和骨传导特性,因此已被广泛用作生物移植物的替代品。新颖的工作已成功地将生物玻璃(BG)引入(ⅰ)羟基磷灰石,(ⅱ)八磷酸钙和(ⅲ)氟羟基磷灰石水泥中,而不会影响固化时间。这项研究的目的是研究在羊股骨con临界尺寸缺损植入后这三种新型BG / CPC水泥的骨形成和接触。我们的假设是,与市售的磷酸钙水泥(Hydroset™)相比,新型水泥将增加同等数量的骨形成。方法:在6只雌性骨骼成熟的商业杂交绵羊的股骨内侧con中产生二十四个8×15 mm深的缺陷。所研究的水泥为BG / CPC复合材料,但是磷酸钙成分由(1)OCP /硬脂石(OCP),(2)氟羟基磷灰石(FHA)或(3)羟基磷灰石(HA)组成。将各组与(4)Hydroset™(可商购的磷酸钙水泥)进行比较。水泥在体内保持12周(n = 6)。荧光色素标记物用于测量骨并置率,取回后,对标本进行未脱钙的组织学处理。穿过每个缺损的中心进行薄切片,并使用图像分析技术量化术后12周的骨并置率和骨与种植体的接触。取回后,使用压痕法(Zwick Praline 500)测试每种水泥的抗压强度(MPa)。使用Mann Whitney U检验进行统计分析,其中p <0.05被认为是显着的。结果:结果表明,与OCP填充(平均0.740±0.156μm/ day-1)相比,Hydroset™组的并置率显着提高(平均1.191±0.345μm/ day-1)(p = 0.028)和FHA缺陷(平均0.839±0.141μm/ day-1)(p = 0.047)。比较Hydroset™和HA样品时,没有发现显着差异。与OCP样品相比,在HA水泥附近测得的骨周转率显着提高(平均值为1.151±0.274μm/ day-1)(p-0.028)。没有发现其他显着差异。 OCP组的骨水泥接触量最大(平均95.47±3.22%)。在HA样品中测得的最低骨水泥接触值(平均值为93.02±2.32%)。与FHA样品相比,在HA样品中测得的骨接触明显更少(平均值为94.55±1.77%)(p = 0.014)。没有发现其他显着差异(图1)。机械测试表明,每个组中的水泥抗压强度都相似(图2)。光和反向散射扫描电子显微镜显示,成熟的层状骨与所有水泥表面接触(图3)。结论:羟基磷灰石晶格中氟化物的掺入以及OCP / Brushite BG / CPC的形成具有与市售磷酸钙水泥Hydroset™一样的生物活性。这些粘固剂能够注射,一旦凝固,在体内12周后其抗压强度就表明它们可能是极好的骨空隙填充剂,并可能在椎体成形术中具有潜在的用途。需要做进一步的工作来评估水泥随时间的再吸收性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号